CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic Targeting
Songul Kucukcelebi, Aniek E. van Diepen, Judith de Vos-Geelen, Casper H. J. van Eijck, Nadine van Montfoort, Casper W. F. van Eijck · 2026
Read CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic Targeting by Songul Kucukcelebi, Aniek E. van Diepen, Judith de Vos-Geelen, Casper H. J. van Eijck, Nadine van Montfoort, Casper W. F. van Eijck (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13255695.txt.
Description
Songul Kucukcelebi and co-authors wrote a 2026 review of CD40 agonists, immune-activating antibodies, for pancreatic ductal adenocarcinoma. This cancer resists most immunotherapy because its dense, myeloid-heavy surroundings keep killer cells out and suppress those that enter. CD40 is a switch on antigen-presenting cells that can wake the immune system up.
Activating CD40 can prime T cells and reshape the suppressive cell mix inside tumors. The review covers where CD40 appears in this cancer, how its signaling works, and how agonist drugs have performed in trials so far. Single agents look insufficient, so combinations with chemotherapy, checkpoint blockers, or vaccines are the realistic path. The authors also warn that simple CD40 levels will not pick the right patients, and better activity markers are needed.
Catalog record
| CREATOR | Songul Kucukcelebi, Aniek E. van Diepen, Judith de Vos-Geelen, Casper H. J. van Eijck, Nadine van Montfoort, Casper W. F. van Eijck |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |